Immuneering's Atebimetinib Data Shows Rare Resistance, Boosting Pancreatic Cancer Survival Potential
Summary
Immuneering Corp. presented new genetic data at the AACR Annual Meeting for its lead drug, atebimetinib, demonstrating that acquired MAPK pathway alterations, common resistance mechanisms for RAS inhibitors, are rarely seen in treated patients. This finding provides a strong molecular rationale for atebimetinib's observed durable tumor shrinkage and supports its potential for improved durability and survival in first-line pancreatic cancer and other RAS-mutant tumors. This positive data significantly de-risks the drug's profile and strengthens its competitive positioning, building on the company's previously stated progression of atebimetinib. Investors will now watch for the planned dosing of the first patient in the pivotal Phase 3 MAPKeeper 301 trial for first-line metastatic pancreatic cancer in mid-2026, and a Phase 2 trial in NSCLC in the second half of the year.
At the time of this announcement, IMRX was trading at $5.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $359.5M. The 52-week trading range was $1.10 to $10.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.